Evidence map›Paper›PMID 40851898›Full record

ArticleJAC-antimicrobial resistance2025

Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible

Ryo Yamaguchi, Takehito Yamamoto, Sohei Harada, Mayu Shibuya, Miyuki Mizoguchi, Yoshimi Higurashi, Miho Echizenya, Takeya Tsutsumi, Tappei Takada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryo YamaguchiDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2012-0299
Takehito YamamotoDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Sohei HaradaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3073-6564
Mayu ShibuyaDepartment of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Miyuki MizoguchiDepartment of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Yoshimi HigurashiDepartment of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Miho EchizenyaDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Takeya TsutsumiDepartment of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The objective of this study was to determine the pharmacokinetic/pharmacodynamic parameters of teicoplanin associated with optimal outcomes in glycopeptide-susceptible Patients and methods: We conducted a retrospective review of GSEF bacteraemia cases treated with teicoplanin between 1 April 2009 and 30 May 2023. Total area under the concentration-time curve over 24 h (AUC Results: A total of 76 patients were included. Treatment failure occurred in 18 patients (23.7%). A CART-derived teicoplanin fAUC Conclusions: An fAUC

Identifiers

PMID40851898
PMCPMC12368495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.